NBY - NovaBay Pharmaceuticals, Inc.
| Previous Close | 1.1994 |
| Open | 1.1600 |
| Bid | 1.20 x 3000 |
| Ask | 1.25 x 800 |
| Day's Range | 1.1500 - 1.2300 |
| 52 Week Range | 0.9700 - 4.2000 |
| Volume | 4,077 |
| Avg. Volume | 22,657 |
| Market Cap | 21.02M |
| Beta (3Y Monthly) | -0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 |
| Earnings Date | Nov 8, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.75 |
- Business Wire•27 days ago
NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results
Conference call begins today at 4:30 p.m. Eastern time
- Business Wire•last month
NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14.
- Zacks•last month
Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
NovaBay Pharmaceuticals Names Jack McGovern Interim CEO
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that Jack McGovern has been named Interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the Company’s previous Chief Executive Officer, remains NovaBay’s Chairman and will focus on strategic growth opportunities that complement the Company’s continued organic growth.
- Business Wire•3 months ago
NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C.
- Business Wire•4 months ago
NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results
Conference call begins today at 4:30 p.m. Eastern time
- ACCESSWIRE•4 months ago
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...
- Business Wire•4 months ago
NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7.
- Business Wire•5 months ago
NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of whom have significant experience in promoting prescription ophthalmic products,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO.
- Business Wire•7 months ago
NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months ended March 31, 2018 and provides a business update.
- Business Wire•7 months ago
NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10.
- Business Wire•9 months ago
NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2017 and provides a business update.
- ACCESSWIRE•9 months ago
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 20, 2018, at 4:30 ...
- Benzinga•9 months ago
NovaBay Pharmaceuticals Q4 Earnings Outlook
On Tuesday, NovaBay Pharmaceuticals (NYSE: NBY ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue NovaBay Pharmaceuticals EPS will likely be ...
- Reuters•9 months ago
BRIEF-Jinzi Ham's Unit Scraps Plan To Invest In Novabay Pharma, To Boost Asset Management Subsidiary's Capital
(Correct second bullet to boost unit’s capital by 90 mln yuan, instead of 90-100 mln yuan) March 1 (Reuters) - Jinzi Ham Co Ltd : * SAYS UNIT SCRAPS PLAN TO INVEST IN NOVABAY PHARMACEUTICALS INC * SAYS ...
- Business Wire•10 months ago
NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 fourth quarter and full year financial results after market close on Tuesday, March 20.
- Business Wire•10 months ago
NovaBay Pharmaceuticals Completes $6.0 Million Private Placement
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing Avenova®, a prescription product for the domestic eye care market, announces the completion of a private placement of 1.7 million shares of common stock to OP Financial Investments Limited for gross proceeds of $5,984,000.
- Business Wire•11 months ago
NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that sales for the fourth quarter of 2017 are expected to slightly exceed $6 million, an increase of more than 49% over the prior-year period.
- Business Wire•last year
NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces stockholder approval to issue NovaBay common stock as part of a $10.32 million financing agreement with Ch-gemstone Capital Co., Ltd.
- Business Wire•last year
NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova lid and lash hygiene for the domestic eye care market, announces that it has regained compliance with NYSE American continued listing standards.
- Capital Cube•last year
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NovaBay Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NBY-US. Comparing the performance and risk of NovaBay Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
